The Critical Role of mRNA Capping in Therapeutic mRNA Production

Enzymatic capping is one of the main ways to synthesize mRNA with Cap structure. Cappin genzyme is essential for enzymatic capping process. The cap structure can increase mRNA/stability, reduce immunogenicity and enable the mRNA to be successfully recognized by ribosomes to initiate the subsequent translation program, compared with co-transcriptional capping, enzymatic capping can form a native Cap 1 structure with low immunogenicity and has a higher capping rate, which can approach 100% after optimization.

Hzymes offers a high-quality Vaccinia virus capping enzyme optimized for in vitro mRNA synthesis in research, clinical, and commercial applications.

The Vaccinia Virus Capping Enzyme (VCE) catalyzes the conversion of Cap0 to Cap1 structures on in vitro transcribed mRNA, essential for therapeutic mRNA stability and translation efficiency. Hzymes VCE is manufactured under GMP conditions with DMF Type II filing support for regulatory submissions.

What Is Vaccinia Virus Capping Enzyme?

The Vaccinia virus capping enzyme (VCE) is a multi-functional enzyme that catalyzes the formation of the 5′ Cap 0 and Cap 1 structures on synthetic mRNA. This native capping method closely mimics natural mRNA capping in eukaryotic cells, resulting in transcripts with high translational efficiency and minimal immune activation.

Unlike co-transcriptional capping methods, which often lead to incomplete or Cap 0 capping, enzymatic capping can achieve near 100% Cap 1 capping efficiency, critical for the success of mRNA vaccines and therapeutics.

Features

1. Higher capping rate and protein expression level than other suppliers

2. GMP-grade, animal-origin-free (AOF), DMF record: 036856.

3. Low impurity: no nuclease /HCD/HCP/microorganism/metal ion residue; endotoxin residue is low.

4. Good thermal stability and freeze-thaw stability.

Performance

The protein expression level of EGFP mRNA synthesized with vaccinia virus capping enzyme from Hzymes and other suppliers is different.

Ordering

Applications in mRNA Therapeutics and Vaccine Development

Hzymes' Vaccinia virus capping enzyme is optimized for:

• IVT mRNA vaccines (e.g., for COVID-19, cancer immunotherapy)
• mRNA-based gene therapies
• Research-use or cGMP-grade manufacturing, scalable from bench to clinic

Its performance and compliance make it an ideal choice for mRNA drug developers, biotech firms, and CDMOs seeking scalable, regulatory-ready solutions.

Why Choose Hzymes as Your mRNA Capping Partner?

Hzymes is a trusted partner in the global biopharmaceutical industry, known for:

• High-performance enzymes and reagents
• Robust QC and technical support
• Global supply capabilities
• End-to-end support for mRNA process development

Our Vaccinia virus capping enzyme is trusted by leading mRNA companies and supports innovation across therapeutic pipelines.

Conclusion: Optimize Your mRNA Workflow with Hzymes

Efficient capping is essential to high-quality mRNA production. Hzymes’ Vaccinia virus capping enzyme offers unmatched performance, purity, and regulatory support, helping you advance from discovery to clinic with confidence.